Associated Papers
The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution.
Nguyen DD et al.
Nature, 2024
39385020 (PubMed )
Supplement: 41586_2024_7955_MOESM11_ESM.xlsx › Figure_3e
Computational refinement identifies functional destructive single nucleotide polymorphisms associated with human retinoid X receptor gene.
Sarkar S et al.
Journal of Biomolecular Structure & Dynamics, 2023
Comprehensive characterization of protein-protein interactions perturbed by disease mutations.
Cheng F et al.
Nature Genetics, 2021
Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer.
Vandekerkhove G et al.
Nature Communications, 2021
33420073 (PubMed )
Supplement: 41467_2020_20493_MOESM3_ESM.xlsx › Supplementary_Data_4
Deep Genomic Sequencing of Bladder Urothelial Carcinoma in Southern Chinese Patients: A Single-Center Study.
Li DY et al.
Frontiers in Oncology, 2021
34055593 (PubMed )
Supplement: Table_1.xlsx › genomic_alterations_information
Recurrent activating mutations of PPARγ associated with luminal bladder tumors.
Rochel N et al.
Nature Communications, 2019
Genomic Activation of PPARG Reveals a Candidate Therapeutic Axis in Bladder Cancer.
Goldstein JT et al.
Cancer Research, 2017
Bladder-cancer-associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation.
Halstead AM et al.
Elife, 2017
Pan-urologic cancer genomic subtypes that transcend tissue of origin.
Chen F et al.
Nature Communications, 2017
28775315 (PubMed )
Supplement: 41467_2017_289_MOESM7_ESM.xlsx › mutation_data
Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer.
Ward DG et al.
Plos One, 2016
26901314 (PubMed )
Supplement: pone.0149756.s006.xlsx › Sheet1
Comprehensive molecular characterization of urothelial bladder carcinoma.
Unknown Author
Nature, 2014
Select a paper to view details